Featured Guest: Fereshteh Barei, PhD
This month VaxTherapy is honored to feature our guest, Fereshteh Barei, PhD.
Fereshteh is an academic lecturer at Lyon Catholic University and Schiller American University in Paris. Her research program is focused on portfolio strategy and innovation in product and process issues, post crisis business models and strategy. As a lecturer she discusses the case of business model innovation, product differentiation strategies and evolving R&D systems in international workshops and conferences. In June 2014, she Founded BIONOWIN Santé Ave Association, focused on professional training for pharmaceutical, biotechnology and health care professionals.
Her academic publications are among the most read and cited. She has published a book about Innovation in the Generic Pharmaceutical Industry in Paris in 2019. Her book it titled: Les médicaments génériques: L'évolution d'un produit copié vers une version innovante (French Edition).
Fereshteh often travels within Europe to host workshops and lectures and is based in Paris. Please keep reading to see what she has to say about the latest evolutions on Covid-19 vaccines and treatment solutions.
Latest Evolutions on COVID-19 Vaccines and Treatment Solutions by Drug Repurposing / Repositioning
The Covid-19 pandemic has posed an extraordinary challenge for the pharmaceutical and biotechnology industries. On the other hand, it has also provided new perspectives and vast opportunities to create, innovate, and discover, with regard to treatments and vaccines.
In this rigorous new environment, innovation is no longer just an organizational or company goal but also a societal mission. Perhaps the most important quest for pharmaceutical and biotechnology companies is to find new ways and new business models to shorten the traditionally slow and time-consuming process of developing a new vaccine or efficient, low-risk, low-cost treatment.
For vaccines, mRNA technology and new software are major contributors and they are efficient, but we also need pharmaceutical treatments to win this race. Several subject matter experts (SMEs) and big companies must also strategically collaborate to share the risks and increase their success rate. Acquiring access to new technologies and facilitating extended collaboration emerged from SMEs’ business models has aimed to create value and augmented value. Management mentality and public pressure also acted as catalyzers; they are the other factors that accelerated access to the most efficient vaccines.
Biotechnology and pharmaceutical companies are facing new realities, and the pre-COVID-19 timeline for bringing new products to market is no longer practical. Therefore, biotechnology companies, as major players in the vaccine market, should design new scenarios for their product portfolios to update them and to satisfy not only investors and stakeholders but also global society, which has suffered from the pandemic and is worried about the upcoming months.
The race to develop a vaccine for COVID-19 is taking place on a global scale; perhaps this is one of the best effects of globalization—American, European, Indian, and several Chinese companies create resilient collaboration as a new standard for accelerated innovation cycles to cope with emerging public health needs for efficient preventive vaccines and treatments[1]. And many researchers focus on its utility and evolution alongside its impact on innovation and the innovativeness of companies.
BIONOWIN Santé Avenue Association will be hosting a webinar on COVID-19 Vaccine and Potential Treatment (latest updates on drug repurposing) on January 29, 2021.
About the upcoming webinar hosted by BioNowin Santé Avenue on January 29, 2021. Registration Link
In this webinar, our invited speaker Dr. Pierre Morgon[i] will discuss the latest evolution of COVID-19 vaccines and their efficiency, especially for older subjects. Pr Dr. Sven Stegemann[ii] will discuss the case of treatments that are currently used to fight COVID-19, Dr. Hermann Mucke[iii] will explain how drug repurposing/repositioning has become a pillar of pharmaceutical treatments that are prescribed for COVID-19.
The accelerated infection rates due to the COVID-19 pandemic require fast access to an efficient, affordable, low-risk therapeutic solution. However, it usually takes several years to develop a new drug. This is why the pharmaceutical companies and research centers are trying to find a treatment out of the existing drugs via the so-called drug repurposing and repositioning method. They screen existing molecules, which have been marketed, or are still in the development phase, and try to determine if they can be effective in the treatment of COVID-19. The advantage of this method is lower risk and shorter time for clinical trials/studies. Companies are also searching among thousands of molecules that have not yet found their usefulness.
We hope that our webinars and interviews with experts from Pharmaceutical and Biotechnology can shed some light on these important questions and can inspire others and create new pathways for innovative ideas.
Replays of BIONOWIN Santé Avenue’s past webinars can be found here.
1 How Chinese companies adopt to Covid19? https://www.gartner.com/smarterwithgartner/how-successful-chinese-companies-adapted-to-covid-19/
[i] https://ch.linkedin.com/in/pierremorgon
[ii] https://de.linkedin.com/in/svenstegemann
You may also like the following posts:
Featured Guest: Dr. Nahreen Ahmed shares her perspective on A "Typical" Day in the Covid ICU
How Long Will the Protection From COVID-19 (Coronavirus) Vaccines Last?
Can a 90% Effective Pfizer/BioNTech COVID-19 Vaccine Stop the Coronavirus Pandemic?
Understanding the Benefits and Limitations of Remdesivir: First FDA-Approved Drug for Covid-19
Will there be an End to Covid-19, Coronavirus? An Expert Perspective
How Use of Face Masks Might Reduce the Severity of Covid-19 Disease
Post-COVID Coronavirus Effects in Children and Babies Appear to Be Far Worse Than We Thought
For the Physicians: Tips for Patients’ Concerns About Office Visits During a Pandemic
4 Questions You Must Ask When Sending Your Kids Back to School During the Pandemic
